One of the most harmful side effects of chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN), a common, disabling and dose-limiting side effect of many chemotherapy agents for which there is no effective treatment. A small reduction in dose intensity can cause a significant decrease in relapse-free survival and overall survival. Our preliminary data showed that acupuncture significantly reduced CIPN neurotoxicity symptoms, improved nerve conduction study, and prevented chemotherapy dose reduction due to CIPN. Our central hypothesis is that acupuncture can prevent worsening of CIPN and improve tolerance of chemotherapy in breast and colorectal cancer patients receiving neurotoxin chemotherapy through increasing NGF. Our goal is to determine the effectiveness of acupuncture in reducing CIPN symptoms and preventing chemotherapy dose reduction caused by CIPN in breast and colorectal cancer patients in the neoadjuvant and adjuvant settings. We will conduct a pilot, 60- patient, randomized, placebo-controlled trial to 1) determine the effect f acupuncture on chemotherapy dose reduction, 2) determine the effect of acupuncture on prevent worsening of CIPN, and 3) identify one of the mechanisms of acupuncture in treating CIPN. Our proposed study will integrate acupuncture into oncology practice to improve to improve patients'tolerance of standard chemotherapy. Our study has the potential to identify an effective non-pharmacological treatment for CIPN and to improve cancer patients'tolerance of standard chemotherapy schedule and subsequently improve their relapse-free survival and overall survival.
The findings of this study will provide useful information to design a future larger sample sized, definitive clinical trial to identify an effective non-pharmacological treatment for chemotherapy-induced peripheral neuropathy that would permit a greater percentage of cancer patients to receive optimal neoadjuvant/adjuvant chemotherapy. The findings of this clinical study may shed light on one significant mechanism of acupuncture in treating this condition.
|Bao, Ting; Li, Qing; DeRito, Janice L et al. (2018) Barriers to Acupuncture Use Among Breast Cancer Survivors: A Cross-Sectional Analysis. Integr Cancer Ther 17:854-859|
|Bao, Ting; Li, Susan Q; Dearing, Josh L et al. (2018) Acupuncture versus medication for pain management: a cross-sectional study of breast cancer survivors. Acupunct Med 36:80-87|
|Bao, Ting; Iris Zhi, Wanqing; Vertosick, Emily A et al. (2018) Acupuncture for breast cancer-related lymphedema: a randomized controlled trial. Breast Cancer Res Treat 170:77-87|
|Zhi, W Iris; Ingram, Evan; Li, Susan Qing et al. (2018) Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain. Integr Cancer Ther 17:1079-1086|
|Bao, Ting; Seidman, Andrew; Li, Qing et al. (2018) Living with chronic pain: perceptions of breast cancer survivors. Breast Cancer Res Treat 169:133-140|
|Bao, Ting; Seidman, Andrew D; Piulson, Lauren et al. (2018) A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. Eur J Cancer 101:12-19|
|Brami, Cloé; Bao, Ting; Deng, Gary (2016) Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol 98:325-34|
|Bao, Ting; Basal, Coby; Seluzicki, Christina et al. (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159:327-33|
|Bao, Ting; Cai, Ling; Snyder, Claire et al. (2014) Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 120:381-9|
|Bao, Ting; Goloubeva, Olga; Pelser, Colleen et al. (2014) A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther 13:396-404|
Showing the most recent 10 out of 12 publications